First-line therapy of chronic myeloid leukemia – focus on dasatinib
Philip C AmreinHematology-Oncology, Massachusetts General Hospital, Boston, USAAbstract: Dasatinib is a broad spectrum, ATP-competitive, tyrosine kinase inhibitor with low nM activity against Bcr-Abl, Src, and other tyrosine kinases. This activity has allowed dasatinib to emerge as one of the most e...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-04-01
|
| Series: | Blood and Lymphatic Cancer: Targets and Therapy |
| Online Access: | http://www.dovepress.com/first-line-therapy-of-chronic-myeloid-leukemia-ndash-focus-on-dasatini-a9750 |